Neil McHugh1,2,3, Áine Maguire4,5,6, Ian Handel4,5,6, William Tillett4,5,6, James Morris4,5,6, Neil Hawkins4,5,6, Charlotte Cavill4,5,6, Eleanor Korendowych4,5,6, Farhan Mughal4,5,6. 1. From the Royal National Hospital for Rheumatic Disease, NHS Foundation Trust, Bath; University of Cambridge, Cambridge; Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh; University of Bath, Bath; Cogentia Healthcare Consulting Ltd., Cambridge; University of Glasgow, Glasgow; and Celgene Ltd., Uxbridge, UK. n.j.mchugh@bath.ac.uk. 2. J. Morris has received consultancy fees from Celgene Ltd. N. Hawkins and C. Cavill have received grant/research support from Celgene Ltd. F. Mughal was an employee of Celgene Ltd. at the time the study was conducted. n.j.mchugh@bath.ac.uk. 3. N. McHugh, MB, ChB, MD, FRCP, Royal National Hospital for Rheumatic Diseases, NHS Foundation Trust, and Department of Pharmacy and Pharmacology, University of Bath; Á. Maguire, MSc, PhD student, Department of Psychology, University of Cambridge; I. Handel, PhD, MS, BVSc, Royal (Dick) School of Veterinary Studies, University of Edinburgh; W. Tillett, BSc, MB, ChB, MRCP, Royal National Hospital for Rheumatic Diseases, NHS Foundation Trust, and the Department of Pharmacy and Pharmacology, University of Bath; J. Morris, MPH, Cogentia Healthcare Consulting Ltd.; N. Hawkins, PhD, Health Economics and Health Technology Assessment, University of Glasgow; C. Cavill, BSc, Royal National Hospital for Rheumatic Diseases, NHS Foundation Trust; E. Korendowych, PhD, MRCP, Royal National Hospital for Rheumatic Diseases, NHS Foundation Trust; F. Mughal, MPharm, Celgene Ltd. (formerly). n.j.mchugh@bath.ac.uk. 4. From the Royal National Hospital for Rheumatic Disease, NHS Foundation Trust, Bath; University of Cambridge, Cambridge; Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh; University of Bath, Bath; Cogentia Healthcare Consulting Ltd., Cambridge; University of Glasgow, Glasgow; and Celgene Ltd., Uxbridge, UK. 5. J. Morris has received consultancy fees from Celgene Ltd. N. Hawkins and C. Cavill have received grant/research support from Celgene Ltd. F. Mughal was an employee of Celgene Ltd. at the time the study was conducted. 6. N. McHugh, MB, ChB, MD, FRCP, Royal National Hospital for Rheumatic Diseases, NHS Foundation Trust, and Department of Pharmacy and Pharmacology, University of Bath; Á. Maguire, MSc, PhD student, Department of Psychology, University of Cambridge; I. Handel, PhD, MS, BVSc, Royal (Dick) School of Veterinary Studies, University of Edinburgh; W. Tillett, BSc, MB, ChB, MRCP, Royal National Hospital for Rheumatic Diseases, NHS Foundation Trust, and the Department of Pharmacy and Pharmacology, University of Bath; J. Morris, MPH, Cogentia Healthcare Consulting Ltd.; N. Hawkins, PhD, Health Economics and Health Technology Assessment, University of Glasgow; C. Cavill, BSc, Royal National Hospital for Rheumatic Diseases, NHS Foundation Trust; E. Korendowych, PhD, MRCP, Royal National Hospital for Rheumatic Diseases, NHS Foundation Trust; F. Mughal, MPharm, Celgene Ltd. (formerly).
Abstract
OBJECTIVE: This analysis aimed to evaluate the economic burden of patients with psoriatic arthritis (PsA) on the UK healthcare system and estimate the relationship between functional status and direct healthcare costs. METHODS: Functional status [measured using the Health Assessment Questionnaire-Disability Index (HAQ-DI)], demographics, disease history, and healthcare resource use data were extracted from a cohort of patients at the Royal National Hospital for Rheumatic Diseases, Bath, UK. Each resource use item per patient was then allocated a unit cost. Linear regression models were used to predict costs as a function of HAQ-DI. Medication costs were not included in the primary analysis, which was carried out from the UK National Health Service perspective. RESULTS: Data were available for 101 patients. Mean HAQ-DI score was 0.84 (SD 0.75) and mean age at HAQ-DI measurement was 57.8 (SD 10.7). Total annual healthcare costs per patient, excluding medication costs, ranged between £174 and £8854, with a mean of £1586 (SD £1639). A 1-point increase in HAQ-DI score was associated with an increase in total costs of £547.49 (standard error £224), with secondary care consultations appearing to be the primary factor. Subgroup analyses suggested higher cost increases in patients with HAQ-DI scores of 2-3 and with a disease duration > 10 years. CONCLUSION: Patients with PsA place a significant economic burden on the healthcare system. Functional status is highly correlated with costs and appears to be driven mainly by the cost of secondary care consultations. Results were similar to previous studies in rheumatoid arthritis populations.
OBJECTIVE: This analysis aimed to evaluate the economic burden of patients with psoriatic arthritis (PsA) on the UK healthcare system and estimate the relationship between functional status and direct healthcare costs. METHODS: Functional status [measured using the Health Assessment Questionnaire-Disability Index (HAQ-DI)], demographics, disease history, and healthcare resource use data were extracted from a cohort of patients at the Royal National Hospital for Rheumatic Diseases, Bath, UK. Each resource use item per patient was then allocated a unit cost. Linear regression models were used to predict costs as a function of HAQ-DI. Medication costs were not included in the primary analysis, which was carried out from the UK National Health Service perspective. RESULTS: Data were available for 101 patients. Mean HAQ-DI score was 0.84 (SD 0.75) and mean age at HAQ-DI measurement was 57.8 (SD 10.7). Total annual healthcare costs per patient, excluding medication costs, ranged between £174 and £8854, with a mean of £1586 (SD £1639). A 1-point increase in HAQ-DI score was associated with an increase in total costs of £547.49 (standard error £224), with secondary care consultations appearing to be the primary factor. Subgroup analyses suggested higher cost increases in patients with HAQ-DI scores of 2-3 and with a disease duration > 10 years. CONCLUSION:Patients with PsA place a significant economic burden on the healthcare system. Functional status is highly correlated with costs and appears to be driven mainly by the cost of secondary care consultations. Results were similar to previous studies in rheumatoid arthritis populations.
Authors: Pedro Santos-Moreno; Fernando Gómez-De la Rosa; Devian Parra-Padilla; Nelson J Alvis-Zakzuk; Nelson R Alvis-Zakzuk; María Carrasquilla-Sotomayor; Omaira Valencia; Nelson Alvis-Guzmán Journal: Psoriasis (Auckl) Date: 2021-03-18
Authors: Suzan Attar; Amjad M Almanmmas; Shabab M Alamri; Ahmad W Sindi; Majed T Jobah; Marwan A Bader; Abdulrahman K Alghamdi; Majd Z Sahhaf; Turki A AlAmoudi Journal: Cureus Date: 2022-07-27
Authors: Nienke J Kleinrensink; Frank T Perton; Juliëtte N Pouw; Nanette L A Vincken; Sarita A Y Hartgring; Mylène P Jansen; Saeed Arbabi; Wouter Foppen; Pim A de Jong; Janneke Tekstra; Emmerik F A Leijten; Julia Spierings; Floris P J G Lafeber; Paco M J Welsing; Marloes W Heijstek Journal: BMJ Open Date: 2022-10-10 Impact factor: 3.006